Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial (Q34669641)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

12

object named as

Markku Kaste

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Hugues Chabriat

7

object named as

Hugues Chabriat

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

13

object named as

Lee H Schwamm

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Thomas Truelsen

3

object named as

Thomas Truelsen

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Bjørn A Grønning

6

object named as

Bjørn A Grønning

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Gregory W Albers

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Rüdiger von Kummer

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jens-Kristian S Jensen

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Gabriela M Ravn

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ku-Chou Chang

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Antonio E Davalos

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Gary A Ford

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

James Grotta

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ashfaq Shuaib

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

DIAS-3 Investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

30 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

575-584

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Desmoteplase: discovery, insights and opportunities for ischaemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Endovascular therapy for ischemic stroke with perfusion-imaging selection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized assessment of rapid endovascular treatment of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900047-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(15)00047-2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34669641&oldid=2120246527"